Comparative Pharmacology
Head-to-head clinical analysis: CONSTULOSE versus PLEGISOL IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONSTULOSE versus PLEGISOL IN PLASTIC CONTAINER.
CONSTULOSE vs PLEGISOL IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lactulose is a synthetic disaccharide that is not absorbed in the small intestine. In the colon, it is metabolized by bacteria to short-chain fatty acids, leading to an osmotic effect that draws water into the bowel, thereby softening stools and increasing bowel motility. In hepatic encephalopathy, lactulose acidifies the colonic environment, promoting the conversion of ammonia (NH3) to ammonium (NH4+), which is trapped and excreted in feces.
PLEGISOL is an extracellular-type crystalloid cardioplegic solution used for myocardial protection during cardiac surgery. Its mechanism involves inducing rapid cardiac arrest by high potassium concentration (depolarizing arrest), reducing myocardial oxygen demand, and providing buffering capacity via tromethamine to maintain pH. The solution also contains magnesium to stabilize membranes and mannitol as an osmotic agent to reduce edema.
10-20 g (15-30 mL) orally once daily, increased to 30-45 g (45-60 mL) if needed; or 30-45 g (45-60 mL) orally every 6-8 hours for hepatic encephalopathy.
Administered as an intraperitoneal infusion for organ preservation. Typical adult dose: 2.5-3.0 liters for kidney, 2.5-3.0 liters for liver, 3.0-4.0 liters for pancreas, single dose prior to procurement.
None Documented
None Documented
Not applicable due to minimal systemic absorption; local action in colon. In cases of systemic absorption, half-life is not clinically relevant.
Not applicable; Plegisol is not a systemically active drug. Its cardioplegic effect is immediate upon perfusion into coronary arteries and dissipates upon reperfusion. The solution's components have endogenous half-lives (e.g., potassium: 1-1.5 h in plasma), but this is not clinically relevant for the product.
Primarily fecal (unchanged); minimal systemic absorption (<3%), thus negligible renal excretion.
Plegisol is an extracellular cardioplegic solution; its components (electrolytes and calcium) are not metabolized. Elimination of infused volume occurs primarily via renal excretion (approx. 95%) as unchanged water and electrolytes; minor biliary/fecal elimination (<5%) accounts for negligible electrolyte loss.
Category C
Category C
Osmotic Laxative
Osmotic Laxative